Accuracy of unidimensional and volumetric ultrasound measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patients

被引:22
作者
Gounaris, I. [1 ]
Provenzano, E. [2 ,3 ]
Vallier, A. L. [1 ,2 ]
Hiller, L. [4 ]
Iddawela, M. [1 ,2 ]
Hilborne, S. [2 ]
Taylor, K. [2 ]
Britton, P. [2 ,3 ]
Earl, H. M. [1 ,3 ,5 ]
Sinnatamby, R. [3 ]
机构
[1] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Ctr Oncol, Cambridge CB2 0QQ, England
[2] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Cambridge Breast Unit, Cambridge CB2 2QQ, England
[3] Cambridge Biomed Res Ctr, Natl Inst Hlth Res, Cambridge CB2 0QQ, England
[4] Univ Warwick, Warwick Clin Trials Unit, Coventry CV4 7AL, W Midlands, England
[5] Univ Cambridge, Dept Oncol, Cambridge CB2 0QQ, England
关键词
Breast cancer; Neoadjuvant chemotherapy; Volumetric ultrasound; Pathological response; TUMOR RESPONSE; MAMMOGRAPHY; ULTRASONOGRAPHY; SONOGRAPHY; WOMEN; DOXORUBICIN; TOMOGRAPHY; SIZE;
D O I
10.1007/s10549-011-1454-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pathological complete response (pCR) is an important predictor of long-term survival in patients with breast cancer receiving neoadjuvant chemotherapy (NAC). At present, the accuracy of traditional radiological assessments during treatment in predicting pCR is poor. Unidimensional and 3D volumetric ultrasound measurements prior to, after 4 cycles (mid-treatment), and at the end of 8 cycles (end-treatment) of chemotherapy were available from a subset of 55 patients enrolled in Neo-tAnGo, a National Cancer Research Network (NCRN) UK neoadjuvant chemotherapy breast cancer trial. Proportional changes in longest diameter (LD) and volume as well as absolute residual size thresholds were examined for their ability to predict pCR or pCR plus minimal residual disease (pCR/MRD). Sensitivity, specificity, positive (PPV) and negative predictive values (NPV) and likelihood ratios (LRs) were calculated. Receiver-operator characteristic (ROC) curves and logistic regression models were also constructed. At mid-treatment, neither complete radiological response, nor proportional LD or volume changes were found predictive of final pCR. A small residual tumour volume (a parts per thousand currency sign1 cm(3) vs. > 1 cm(3)) at mid-treatment, however, was associated with pCR/MRD (P = 0.014). Sensitivity, specificity, PPV, NPV, LR+ and LR- values were 61%, 77%, 61%, 77%, 2.62 and 0.51, respectively. The area under the ROC curve was 0.689 (P = 0.03). Volume a parts per thousand currency sign1 cm(3) at mid-treatment was found significant in a logistic regression (OR: 0.194, P = 0.011). At end-treatment, no ultrasound measurements were found predictive of pCR or pCR/MRD. In conclusion, proportional tumour size changes (the basis of the RECIST criteria) were not found predictive of good pathological response, although residual volume a parts per thousand currency sign1 cm(3) at mid-treatment was found to be predictive of pCR/MRD. However, multiple volume and LD thresholds were examined and uncorrected P values presented, increasing the possibility of type I errors. Replication in an independent dataset is required.
引用
收藏
页码:459 / 469
页数:11
相关论文
共 35 条
[1]  
Akashi-Tanaka S, 2001, INT J CANCER, V96, P66, DOI 10.1002/1097-0215(20010220)96:1<66::AID-IJC7>3.0.CO
[2]  
2-T
[3]   Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy [J].
Akazawa, K ;
Tamaki, Y ;
Taguchi, T ;
Tanji, Y ;
Miyoshi, Y ;
Kim, SJ ;
Ueda, S ;
Yanagisawa, T ;
Sato, Y ;
Tamura, S ;
Noguchi, S .
BREAST JOURNAL, 2006, 12 (02) :130-137
[4]   Potential of Reduction in Total Tumor Volume Measured with 3D-MRI as a Prognostic Factor for Locally-Advanced Breast Cancer Patients Treated with Primary Chemotherapy [J].
Akazawa, Kenji ;
Tamaki, Yasuhiro ;
Taguchi, Tetsuya ;
Tanji, Yoshio ;
Miyoshi, Yasuo ;
Kim, Seung Jim ;
Shimazu, Kenzo ;
Ueda, Satsuki ;
Yanagisawa, Tetsu ;
Okishiro, Noritsugu ;
Imazato, Mitsunobu ;
Yasuyuki, Kozuma ;
Sato, Yoshinobu ;
Tamura, Shinichi ;
Noguchi, Shinzaburo .
BREAST JOURNAL, 2008, 14 (06) :523-531
[5]   Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI [J].
Balu-Maestro, C ;
Chapellier, C ;
Bleuse, A ;
Chanalet, I ;
Chauvel, C ;
Largillier, R .
BREAST CANCER RESEARCH AND TREATMENT, 2002, 72 (02) :145-152
[6]   The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27 [J].
Bear, HD ;
Anderson, S ;
Brown, A ;
Smith, R ;
Mamounas, EP ;
Fisher, B ;
Margolese, R ;
Theoret, H ;
Soran, A ;
Wickerham, DL ;
Wolmark, N .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) :4165-4174
[7]  
CHAPGAR AB, 2006, ANN SURG, V243, P257
[8]   The Role of PET CT to Evaluate the Response to Neoadjuvant Chemotherapy in Advanced Breast Cancer: Comparison With Ultrasonography and Magnetic Resonance Imaging [J].
Choi, Jae Hyuck ;
Lim, Hye In ;
Lee, Se Kyung ;
Kim, Wan Wook ;
Kim, Sang Min ;
Cho, Eunyoon ;
Ko, Eun Young ;
Han, Boo-Kyung ;
Park, Yeon Hee ;
Ahn, Jin-Seok ;
Im, Young-Hyuck ;
Lee, Jeong Eon ;
Yang, Jung-Hyun ;
Nam, Seok Jin .
JOURNAL OF SURGICAL ONCOLOGY, 2010, 102 (05) :392-397
[9]  
Earl HM, 2009, J CLIN ONCOL, V27
[10]   Pathological assessment of the response of locally advanced breast cancer to neoadjuvant chemotherapy and its implications for surgical management [J].
El-Didi, MH ;
Moneer, MM ;
Khaled, HM ;
Makarem, S .
SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY, 2000, 30 (03) :249-254